LifeStance Health Group, Inc. (NASDAQ:LFST) Receives $8.83 Consensus PT from Analysts

LifeStance Health Group, Inc. (NASDAQ:LFST) has been given an average recommendation of “Moderate Buy” by the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $8.8333.

A number of brokerages have issued reports on LFST. BMO Capital Markets started coverage on LifeStance Health Group in a research report on Thursday, November 13th. They set an “outperform” rating and a $8.00 price target on the stock. BTIG Research increased their target price on LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Wall Street Zen cut shares of LifeStance Health Group from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Zacks Research cut shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 5th. Finally, UBS Group lifted their target price on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, November 7th.

LifeStance Health Group Stock Performance

Shares of NASDAQ LFST opened at $7.30 on Friday. The company has a market capitalization of $2.84 billion, a PE ratio of -243.33 and a beta of 1.12. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.58 and a current ratio of 1.58. The company’s fifty day moving average price is $6.51 and its 200 day moving average price is $5.52. LifeStance Health Group has a 1 year low of $3.74 and a 1 year high of $8.30.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.03. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The company had revenue of $363.81 million during the quarter, compared to analysts’ expectations of $355.06 million. During the same quarter in the previous year, the company earned ($0.02) earnings per share. The firm’s revenue for the quarter was up 16.3% on a year-over-year basis. On average, research analysts predict that LifeStance Health Group will post -0.18 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Robert Bessler sold 119,942 shares of LifeStance Health Group stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $7.04, for a total value of $844,391.68. Following the sale, the director directly owned 1,318,983 shares of the company’s stock, valued at $9,285,640.32. The trade was a 8.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Ann Varanakis sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $6.90, for a total value of $345,000.00. Following the sale, the insider owned 315,610 shares of the company’s stock, valued at $2,177,709. The trade was a 13.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 327,326 shares of company stock worth $2,259,317. Insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On LifeStance Health Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jacobs Levy Equity Management Inc. acquired a new position in shares of LifeStance Health Group during the 1st quarter valued at about $7,932,000. Squarepoint Ops LLC raised its stake in LifeStance Health Group by 259.1% during the second quarter. Squarepoint Ops LLC now owns 1,360,054 shares of the company’s stock worth $7,031,000 after purchasing an additional 981,349 shares during the period. OLD National Bancorp IN acquired a new position in LifeStance Health Group in the 3rd quarter valued at about $508,000. Adage Capital Partners GP L.L.C. boosted its holdings in LifeStance Health Group by 43.8% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 230,000 shares of the company’s stock valued at $1,532,000 after purchasing an additional 70,000 shares during the last quarter. Finally, AXQ Capital LP purchased a new stake in shares of LifeStance Health Group in the 2nd quarter valued at approximately $343,000. Institutional investors and hedge funds own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.